Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC) : A Randomised Controlled Study
Palou, Juan (Institut d'Investigació Biomèdica Sant Pau)
Sanguedolce, Francesco (Institut d'Investigació Biomèdica Sant Pau)
Sancho-Pardo, Gemma (Institut d'Investigació Biomèdica Sant Pau)
Romancik, Martin (Department of Urology, St. Cyril and Methodius Hospital, Bratislava, Slovakia)
Vittori, Gianni (Careggi University Hospital (Florència, Itàlia))
Minervini, Andrea (Careggi University Hospital (Florència, Itàlia))
Di Maida, Fabrizio (Careggi University Hospital (Florència, Itàlia))
Lunik, Richard (Remedium Clinic, Bardejov, Slovakia)
Colombo, Renzo (Vita Salute San Raffaele University and Urological Research Institute, San Raffaele Hospital, Milan, Italy)
Serretta, Vincenzo (Department of Urology, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy)
Çetinel, Bülent (Department of Urology, Cerrahpaşa Medical School, Istanbul University, Istanbul, Turkey)
Bini, Vittorio (Department of Medicine, University of Perugia, Perugia, Italy)
Corradengo, Davide (Ospedale Policlinico San Martino IRCCS, Genova, Italy)
Lazzeri, Massimo (Humanitas Research Hospital (Itàlia))
Universitat Autònoma de Barcelona

Fecha:	2021
Resumen:	Radiation-induced cystitis is a common side effect of radiotherapy (RT) to the pelvic area. Hyaluronic acid (HA) and chondroitin sulfate (CS) are components of the urothelial mucosa and positive results have been obtained for intravesical HA/CS instillations for the treatment of urinary tract infections and bladder pain syndrome. HA/CS may also have a protective effect against RT bladder toxicity. To investigate whether HA and CS protect the urothelium during RT, alleviate lower urinary tract symptoms, and improve quality of life. This multicentre randomised controlled trial was conducted across seven centres in four countries. Male patients aged ≥18 yr scheduled to undergo primary intensity-modulated radiotherapy for localised prostate cancer were enrolled. Patients were randomised to intravesical HA/CS plus an oral formulation of curcumin, quercetin, HA, and CS (group A) or no treatment (group B). The primary endpoint was absolute changes from baseline to follow-up in urinary domain scores for the Expanded Prostate Cancer Index Composite (EPIC), the International Consultation on Incontinence Questionnaire-Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), and the EuroQol Group EQ-5D-5L questionnaire. Data analysis for efficacy and safety outcomes was performed using an intention-to-treat (ITT) approach; the ITT population was defined as all randomised patients. Of 57 patients screened, 49 were enrolled and randomly assigned to either active treatment (group A, n = 25) or the control (group B, n = 24). Three patients in the control group withdrew after randomisation. Changes from baseline to 12 mo were worse in the control group for subtotal scores for urinary symptoms and impact of symptoms on quality of life and for the total score (p = 0. 05, p = 0. 003, and p = 0. 008, respectively). There was a significant time × group interaction in favour of active treatment for the incontinence symptom score (p = 0. 011) and bother score (p = 0. 017). The absence of a sham procedure and/or placebo is the main limitation. Our results suggest that intravesical HA/CS in combination with an oral formulation may reduce urinary symptoms and improve QoL at short-term (1 yr) follow-up. We investigated whether hyaluronic acid (HA) and chondroitin sulfate (CS) have a protective effect against the bladder toxicity of radiotherapy for prostate cancer. HA/CS used for weekly bladder irrigation for 6 wk and given orally with curcumin and quercetin for 12 wk reduced urinary incontinence symptoms and bother measured at 1-year follow-up. This may hold promise as a preventive treatment if the results are confirmed in further trials. Our findings show a beneficial effect of intravesical hyaluronic acid (HA)/chondroitin sulfate (SC) plus the oral combination of curcumin, quercetin, HA, and CS for prevention of acute and late (1 yr) radiation-induced cystitis and improvement in quality of life. The current strategy may have a place among treatment options for the prevention of radiation-induced bladder complications, which until now have been limited to symptom-relieving and temporary modalities.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Prostate cancer ; Radiotherapy ; Cystitis ; Hyaluronic acid ; Chondroitin sulfate ; Questionnaries ; Quality of life ; Lower urinary tract symptoms
Publicado en:	European Urology Open Science, Vol. 26 (february 2021) , p. 45-54, ISSN 2666-1683

DOI: 10.1016/j.euros.2021.01.016
PMID: 34337507

10 p, 1.3 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados